Recommended Topic Related To:

Privigen

"A unique type of poster placed in exam rooms helped reduce unnecessary antibiotic prescriptions for respiratory infections during flu season. The approach could help reduce costs and extend the usefulness of these drugs.

Antibiotics a"...

Privigen

Privigen

INDICATIONS

Treatment of Primary Immunodeficiency

Privigen™ (immune globulin intravenous) is indicated for the treatment of patients with primary immunodeficiency (PI) associated with defects in humoral immunity. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Treatment of Chronic Immune Thrombocytopenic Purpura

Privigen™ (immune globulin intravenous) is indicated for the treatment of patients with chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding.

DOSAGE AND ADMINISTRATION

Preparation and Handling

Privigen™ (immune globulin intravenous) is a clear or slightly opalescent, colorless to pale yellow solution. Privigen™ (immune globulin intravenous) should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. Any solution that has been frozen must not be used. DO NOT SHAKE.

Do not mix Privigen™ (immune globulin intravenous) with other IGIV products or other intravenous medications. If necessary, Privigen™ (immune globulin intravenous) can be diluted with Dextrose Injection, USP (D5W). If large doses of Privigen™ (immune globulin intravenous) are to be administered, several vials may be pooled using aseptic technique.

The Privigen™ (immune globulin intravenous) vial is for single use only. Once the vial has been entered under aseptic conditions, its contents should be used promptly. Because the solution contains no preservative, Privigen™ (immune globulin intravenous) should be infused as soon as possible. Any unused product or waste material should be disposed of in accordance with local requirements.

Treatment of Primary Immunodeficiency

The usual dose of Privigen™ (immune globulin intravenous) for patients with PI is 200 to 800 mg/kg, administered every 3 to 4 weeks. An optimum target serum immunoglobulin G (IgG) trough level has not been established in randomized, controlled clinical studies. Doses should be adjusted to achieve the desired serum trough levels and clinical responses.

The recommended initial infusion rate is 0.5 mg/kg/min (0.005 mL/kg/min). If the infusion is well tolerated, the rate may be gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min). For patients judged to be at risk of renal dysfunction or thrombotic events, Privigen™ (immune globulin intravenous) should be administered at the minimum infusion rate practicable (see WARNINGS and PRECAUTIONS).

Treatment of Chronic Immune Thrombocytopenic Purpura

The usual dose of Privigen™ (immune globulin intravenous) for patients with chronic ITP is 1 g/kg administered daily for 2 consecutive days, resulting in a total dosage of 2 g/kg.

The recommended initial infusion rate is 0.5 mg/kg/min (0.005 mL/kg/min). If the infusion is well tolerated, the rate may be gradually increased to a maximum of 4 mg/kg/min (0.04 mL/kg/min). For patients judged to be at risk of renal dysfunction or thrombotic events, Privigen™ (immune globulin intravenous) should be administered at the minimum infusion rate practicable (see WARNINGS and PRECAUTIONS).

Administration

Privigen™ (immune globulin intravenous) is for intravenous (IV) administration and should be given by a separate infusion line. An infusion pump may be used to control the rate of administration. The Privigen™ (immune globulin intravenous) infusion line can be flushed with Dextrose Injection, USP (D5W) or 0.9% Sodium Chloride for Injection, USP.

The following patients may be at risk of developing inflammatory reactions on rapid infusion of Privigen™ (immune globulin intravenous) (greater than 4 mg/kg/min [0.04 mL/kg/min]): 1) those who have not received Privigen™ (immune globulin intravenous) or another IgG product; 2) those who are switching from another IgG product; and 3) those who have not received IgG in more than 8 weeks. These patients should be started at a slow rate of infusion (e.g., 0.5 mg/kg/min [0.005 mL/kg/min] or less) and gradually advanced to the maximum rate as tolerated.

Ensure that patients with pre-existing renal insufficiency and those predisposed to acute renal failure are not volume depleted before administering Privigen™ (SEE BOXED WARNING, WARNINGS and PRECAUTIONS).

The patient's vital signs should be observed and monitored carefully throughout the infusion. If side effects occur, the infusion should be slowed or stopped until the symptoms subside. The infusion may then be resumed at a lower rate that is comfortable for the patient.

Dosage Forms And Strengths

5 g in 50 mL solution

10 g in 100 mL solution

20 g in 200 mL solution

HOW SUPPLIED

AND STORAGE AND HANDLING

Privigen™ (immune globulin intravenous) is supplied in a single-use, tamper-evident vial containing the labeled amount of functionally active IgG. The components used in the packaging for Privigen™ (immune globulin intravenous) are latex-free.

The following dosage forms are available:

NDC Number Fill Size (mL) Grams
44206-436-05 50 5
44206-437-10 100 10
44206-438-20 200 20

Each vial has an integral suspension band and a label with two peel-off strips showing the product name, lot number, and expiration date.

When stored at room temperature (up to 25C [77F]), Privigen™ (immune globulin intravenous) is stable for up to 24 months, as indicated by the expiration date printed on the outer carton and vial label. Do not freeze. Keep Privigen™ (immune globulin intravenous) in its original carton to protect it from light.

Manufactured by: CSL Behring AG., Berne, Switzerland. US License No. 1766.
Distributed by: CSL Behring LLC., Kankakee, IL 60901 USA. FDA rev date: 7/26/2007

Last reviewed on RxList: 8/27/2007
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

Related Drugs
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations